ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1059

Inflammatory Cytokines and Adipokines in Obese Patients with and Without CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2302 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Mahajan, Sandeep, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Subbiah, Arunkumar, All India Institute of Medical Sciences, New Delhi, Delhi, India

Global epidemic of obesity & metabolic disorders are fuelling increasing cases of CKD worldwide. Besides having higher incidence of DM & hypertension, obesity is independent risk factor for CKD. Mechanisms involved are poorly studied, though obesity related inflammation mediated by shift in adipokine and cytokine production towards pro-inflammatory state is implicated.
We in this case control study looked at important pro-inflammatory mediators (leptin, IL-6, TNF-α) and anti-inflammatory mediators (adiponectin, IL-10) in obese with & without CKD, non-obese CKD & healthy controls.


50 consenting subjects in each group were studied. Besides detailed history, co-morbidity charting, BMI calculation; serum levels of HsCRP, adipokines (leptin & adiponectin) & cytokines (IL-6, TNF-α & IL-10) were assessed using commercially available ELISA kits.


Table shows demographic, clinical & study parameters of each group. Patient groups had similar representation of DM & were slightly older than controls. Obese subjects with & without CKD had higher HsCRP, leptin & IL6 than controls & CKD patients, with obese patients with CKD showing maximum aberrations. Adiponectin concentration was higher in patients with obesity alone but suppressed in patients with obesity & CKD.


Inflammation & pro-inflammatory milieu as evidenced by high levels of Hs-CRP, IL-6 & leptin and low levels of adiponectin might be important drivers for obesity related complications like CKD. Larger, prospective studies are required to confirm the same.

Demographic, clinical & study parameters of each group
ParameterControlObese without CKDObese with CKDNon-obese CKD
Age (yr)45.7±13.751.1±12.7*50.4±10.8*49.7±12.2*
Male (%)68706872
DM (%)030*32*28*
eGFR (ml/min)81.5±26.484.2±20.841.2±18.2*^38.9±20.2*^
HsCRP (mg/L)1.5±1.44.2±0.4*#$8.7±2.1*^$2.5±1.1*^#
Leptin (ng/ml)2.2±0.64.4±2.7*#$8.8±2.9*^$1.9±0.8^#
Adiponectin (pg/ml)5.1±1.135.3±29.1*#$3.4±0.7*^3.9±0.6*^
IL-6 (pg/ml)44.9±16.3503.4±153.8*#$894.9±370.1*^$254.3±78.2*^#
TNF-α (pg/ml)99.1±12.6113.4±16.1#136.7±21.2*^$101.3±19.1#
IL-10 (pg/ml)82.3±35.9128.9±36.9*#316.3±126.2*^#115.1±18.6*#

*p<0.05 vs group 1, ^ p<0.05 vs group 2, # p<0.05 vs group 3, $ p<0.05 vs group 4


  • Government Support – Non-U.S.